Leerink Partnrs Issues Optimistic Outlook for INSP Earnings

Inspire Medical Systems, Inc. (NYSE:INSP - Free Report) - Research analysts at Leerink Partnrs raised their Q1 2025 earnings estimates for Inspire Medical Systems in a research note issued to investors on Tuesday, February 11th. Leerink Partnrs analyst M. Kratky now forecasts that the company will post earnings per share of ($0.18) for the quarter, up from their prior forecast of ($0.25). The consensus estimate for Inspire Medical Systems' current full-year earnings is $1.33 per share. Leerink Partnrs also issued estimates for Inspire Medical Systems' Q2 2025 earnings at $0.46 EPS, Q3 2025 earnings at $0.60 EPS, Q4 2025 earnings at $1.25 EPS, FY2025 earnings at $2.14 EPS, FY2026 earnings at $3.28 EPS, FY2027 earnings at $4.27 EPS and FY2029 earnings at $6.80 EPS.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last released its quarterly earnings data on Monday, February 10th. The company reported $1.15 EPS for the quarter, beating analysts' consensus estimates of $0.74 by $0.41. Inspire Medical Systems had a net margin of 4.37% and a return on equity of 5.30%.

Other equities research analysts have also issued reports about the stock. Wells Fargo & Company dropped their target price on shares of Inspire Medical Systems from $198.00 to $195.00 and set an "equal weight" rating for the company in a research report on Tuesday. Royal Bank of Canada reiterated an "outperform" rating and set a $260.00 target price on shares of Inspire Medical Systems in a research report on Tuesday. Morgan Stanley dropped their target price on shares of Inspire Medical Systems from $230.00 to $220.00 and set an "overweight" rating for the company in a research report on Tuesday. KeyCorp reiterated an "overweight" rating and set a $234.00 target price (down from $236.00) on shares of Inspire Medical Systems in a research report on Friday, January 24th. Finally, Bank of America upgraded shares of Inspire Medical Systems from a "neutral" rating to a "buy" rating and lifted their target price for the company from $220.00 to $255.00 in a research report on Wednesday, November 20th. Three research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $228.82.

Inspire Medical Systems Trading Down 1.3 %

Shares of INSP stock traded down $2.42 during trading hours on Thursday, reaching $184.73. The stock had a trading volume of 680,965 shares, compared to its average volume of 564,408. The stock's fifty day simple moving average is $189.11 and its 200 day simple moving average is $191.33. Inspire Medical Systems has a 12 month low of $123.00 and a 12 month high of $257.40. The firm has a market capitalization of $5.54 billion, a PE ratio of 172.65 and a beta of 1.32.

Insiders Place Their Bets

In related news, CTO John Rondoni sold 583 shares of Inspire Medical Systems stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $170.49, for a total value of $99,395.67. Following the transaction, the chief technology officer now directly owns 10,424 shares of the company's stock, valued at $1,777,187.76. The trade was a 5.30 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 4.10% of the company's stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. First Horizon Advisors Inc. increased its stake in shares of Inspire Medical Systems by 885.7% in the fourth quarter. First Horizon Advisors Inc. now owns 138 shares of the company's stock worth $26,000 after buying an additional 124 shares during the period. True Wealth Design LLC purchased a new position in shares of Inspire Medical Systems in the third quarter worth $30,000. Farther Finance Advisors LLC increased its stake in shares of Inspire Medical Systems by 1,158.3% in the third quarter. Farther Finance Advisors LLC now owns 151 shares of the company's stock worth $32,000 after buying an additional 139 shares during the period. Huntington National Bank increased its stake in shares of Inspire Medical Systems by 228.3% in the fourth quarter. Huntington National Bank now owns 174 shares of the company's stock worth $32,000 after buying an additional 121 shares during the period. Finally, GAMMA Investing LLC boosted its holdings in Inspire Medical Systems by 559.3% in the third quarter. GAMMA Investing LLC now owns 178 shares of the company's stock valued at $38,000 after acquiring an additional 151 shares in the last quarter. 94.91% of the stock is owned by hedge funds and other institutional investors.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.